Pierre Etienne, Author at Actu-Real

January 29, 2024

Is ChatGPT capable of making moral judgments related to health and well-being?

by Pierre Etienne in Actu-Real Blog

In March last year, we submitted to ChatGPT the example of a moral dilemma from Gawronski & Beer (2016) (see reference below) with proscriptive norm and action that increases overall well-being. At the time, we did not succeed in forcing ChatGPT to make a moral judgment. We resubmitted exactly the same dilemma with an explicit […]

May 1, 2023

Is ChatGPT capable of resolving moral dilemmas?

by Pierre Etienne in Actu-Real Blog

Exercise with ChatGPT Mar 23 Version: Is ChatGPT capable of making moral judgments related to health and well-being? April 5, 2023 Example: We selected an example of moral dilemma with proscriptive norm and action that increases overall well-being from Gawronski & Beer (2016) (See reference below). You are the director of a hospital in a […]

January 30, 2023

Formulary Management Disruptiveness Index and the PBM Rebate to WAC Ratio

by Pierre Etienne in Actu-Real Blog

The ratio of PBM rebate to WAC as a practical measure of non-disruptiveness or formulary interchangeability: Example of Insulin A recent article in Nature(1) suggests that papers and patents are “increasingly less likely to break with the past in ways that push science and technology in new directions”. This pattern holds universally across fields and […]

January 23, 2023

Consequences of Increased Life Expectancy with LEQEMBI treatment for Early AD, on its Estimated Benefits

by Pierre Etienne in Actu-Real Blog

What could be the consequences of increased life expectancy with LEQEMBI treatment for Alzheimer’s Disease, on its estimated benefits? In the news they provided on January 6, 20212 (1), Eisai described their approach to pricing LEQEMBI (Lecanemab), a disease-modifying treatment for early Alzheimer’s Disease (AD). When approved, the treatment is expected to be reserved for […]

November 29, 2022

Impact of CGTs on the real option value of any treatment that extends life

by Pierre Etienne in Actu-Real Blog

Could CGTs increase the real option value of any treatment that extends life? Those who face uncertainty in business can purchase real options to manage their risks. These give them the right, but not the obligation to purchase (or sell) tangible opportunities (in contrast to pure financial opportunities) at a deferred date when they can […]

November 21, 2022

Installment payments for CGTs – A practical solution in the US?

by Pierre Etienne in Actu-Real Blog

Curative cell and gene therapies or CGTs (also referred to as single and short-term treatments or SSTs) present a unique challenge: the requirement to pay a high price in the short-term despite uncertainty about the long-term benefits. If this was the only problem, there is a solution which has been proposed in several forums (1) […]

June 9, 2022

Just How ‘Real’ is Real-World Data?

by Pierre Etienne in Actu-Real Newsroom

Addressing sources of tension on differentiating types of data. A few years ago, many in the life-science industry questioned whether real-world data (RWD) would have any application in drug development. Due to the growing digitalization of healthcare, it is now certain that it has huge potential, especially given the release of FDA guidance concerning the […]

March 1, 2022

Role of healthcare providers expands in dcts

by Pierre Etienne in Actu-Real Newsroom

Even before the COVID pandemic, most clinical trials already had decentralized components such as blood draws completed at locations other than the designated trial site. However, the pandemic created an opportunity for a new decentralized component, telemedicine, with remote visits. Inexpensive telecommunication platforms, immensely popular in ordinary life, became very successful in routine healthcare, as […]

January 18, 2022

MHRA guidance on the use of RWD

by Pierre Etienne in Actu-Real Blog

Leveraging real-world evidence in clinical development Commentary on the MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions (1) and the MHRA guideline on randomized controlled trials using real-world data to support regulatory decisions (2), both recently published (December 16, 2021) MHRA acknowledges that evidence from randomized trials using […]

December 8, 2021

Is the effect of sildenafil on Alzheimer’s disease plausible? A pharmacokinetic perspective

by Pierre Etienne in Actu-Real Blog

There have been many reactions to the retrospective study identifying sildenafil (Viagra) as a candidate drug for Alzheimer’s disease that has just been published in Nature Aging. Despite alternative explanations (and hidden unknowns) the results are generally viewed as enough evidence of an association to justify prospective studies. One issue that I have not seen […]

Mail Us

All posts by: Pierre Etienne

Is ChatGPT capable of making moral judgments related to health and well-being?

Is ChatGPT capable of resolving moral dilemmas?

Formulary Management Disruptiveness Index and the PBM Rebate to WAC Ratio

Consequences of Increased Life Expectancy with LEQEMBI treatment for Early AD, on its Estimated Benefits

Impact of CGTs on the real option value of any treatment that extends life

Installment payments for CGTs – A practical solution in the US?

Just How ‘Real’ is Real-World Data?

Role of healthcare providers expands in dcts

MHRA guidance on the use of RWD

Is the effect of sildenafil on Alzheimer’s disease plausible? A pharmacokinetic perspective

Actu-Real Inc.

Email

Find Us on Social Platforms